Dr. Allan Brasier is a faculty member in the Division of Endocrinology, Diabetes and Metabolism within the Department of Medicine, the Jan and Kathryn Ver Hagen Chair of Clinical and Translational Research, and Senior Associate Dean for Clinical and Translational Research in the School of Medicine and Public Health (SMPH). He serves as Executive Director of the UW Institute for Clinical and Translational Research (ICTR), which is supported by the National Institutes of Health’s Clinical and Translational Science Award (CTSA) program.
Dr. Brasier served on the faculty of the University of Texas Medical Branch in Galveston from 1991 to 2018, where he was director of the Institute for Translational Sciences (ICTS), director of the Sealy Center for Molecular Medicine, and the Nelda C. and H.J. Lutcher Stark Distinguished Professor in the Department of Internal Medicine. He has been granted 10 patents, and his 240 peer-reviewed publications have been cited more than 10,000 times. His leadership of team science programs has enhanced innovative research and increased the development of usable products and medical devices. At ICTR, Dr. Brasier is focusing on evidence-driven approaches to creating and supporting multidisciplinary translational teams to advance precision medicine, improve outcomes in partnership with our health system, and enhance community involvement by deepening ties throughout Wisconsin. Dr. Brasier oversees the administrative team of ICTR and collaborates with partners including Marshfield Clinic, four UW schools (SMPH, School of Nursing, School of Pharmacy, and the School of Veterinary Medicine), as well as the College of Engineering. His portfolio includes Clinical Research Support, Community Engagement, and Team Science.
Dr. Brasier’s practices in a UW Health Endocrinology Clinic. His clinical interests include disorders of calcium metabolism, metabolic bone disease, and osteoporosis.
View Dr. Allan Brasier's publications on NCBI My Bibliography
Dr. Brasier’s research focuses on how cellular signaling pathways induce innate inflammation, a process associated with many chronic diseases, such as asthma, heart disease, inflammatory bowel disease, and cancer. His work has advanced the understanding, at the cellular level, how innate signaling is activated and the intracellular signaling pathways involved. In particular, his work has focused on the NFκB transcription factor, a master regulator of inflammation whose activation results in expression of gene regulatory networks controlling tissue inflammation and cell state changes. His pioneering work has applied advanced bioinformatics to integrate information from high- throughput gene and protein expression studies to generate novel mechanistic insights about this pathway. These studies have extended our understanding of the actions and regulation of NFκB to its role in a unique regulatory process known as transcriptional elongation. His work is informing translational research strategies to reduce viral induced inflammation, airway remodeling, and inflammatory bowel disease. Additional areas of investigation include the applications of proteomics to discover novel predictive biomarkers in patients with inflammatory disease to diagnose subtypes of disease, follow progression and predict treatment outcome as a first step towards personalized medicine.